Introduction
============

Acute bronchospasm is rarely imaged dynamically prior to and following successful therapy. The ability to quantify the presence or degree of bronchospasm and its response to therapies could potentially provide a tool for the analysis of bronchospasm. Recent low-dose CT scans can resolve the edge of the main airways with a fraction of the ionizing radiation.

Case presentation
=================

A 62-year-old man with a long history of smoking and recently diagnosed chronic obstructive pulmonary disease had an acute episode of bronchospasm following a lung biopsy, which was seen dynamically on CT. The CT scan was performed sequentially over a limited field of view to monitor a very small asymptomatic pneumothorax for change in size after a percutaneous biopsy. This afforded the fortuitous opportunity to document the images of acute bronchospasm, including the response to the inhaled bronchodilator albuterol. Radiological and physiological response to albuterol correlated with the clinical resolution of hypoxia.

The patient underwent a biopsy to determine if a recently diagnosed lung mass was a primary lung cancer or recurrent lymphoma. Immediately after the removal of the biopsy needle, a CT scan demonstrated a very small (several mm) asymptomatic pneumothorax. The patient was initially neither wheezing nor dyspneic or tachypneic. Ten minutes later, he suddenly began to wheeze and soon thereafter, his blood oxygen saturation levels suddenly and precipitously dropped from a baseline of 95%--96% to 88%. A second immediate CT scan at the time of wheezing showed simultaneous acute narrowing of the trachea and both main bronchi ([Figure 1A--F](#f1-jaa-5-061){ref-type="fig"}). CT scans prior to wheezing, while wheezing, and after treatment of wheezing and resolution of bronchospasm were each analyzed and measured at five levels for each time point ([Table 1](#t1-jaa-5-061){ref-type="table"}). The main trachea, right and left bronchi origins, and right and left main bronchi were measured in diameter at the same consistent levels, using anatomical landmarks as references. The CT during wheezing was obtained during a breath hold, without motion, on inspiration, and in between breaths. This was identical for all CT scans measured.

During wheezing, the tracheal area dropped by 52%. The areas of the right and left bronchial origins (measured at the carina) decreased by 35% and 34%, respectively. The right and left main bronchial areas decreased by 72% and 68%, respectively. A subsequent CT scan taken 10 minutes after administration of inhaled albuterol and resolution of wheeze showed resolution of size changes back to baseline ([Figure 1G--I](#f1-jaa-5-061){ref-type="fig"}). It is possible, although speculative, that bronchial irritation from the biopsy or trace blood, in the presence of underlying reactive airways, triggered reflex bronchospasm.

Discussion
==========

The dynamic imaging of bronchospasm and its response to therapy was a chance event for this patient. A chest CT is well established as the gold standard in structural imaging of the bronchial tree.[@b1-jaa-5-061] Clinical studies have shown a correlation between airway dimensions on CT and pulmonary function results in chronic obstructive pulmonary disease.[@b2-jaa-5-061] High-resolution CT has been used effectively in assessing bronchial reactivity in asthmatic patients, and in assessing responses to both bronchoconstrictor and bronchodilator drugs.[@b3-jaa-5-061],[@b4-jaa-5-061] With recent advances in CT imaging technology, low-energy, low-dose CT scans could offer a method for noninvasive dynamic measurement of functional airway mechanics. Ultralow-dose CT scans can depict airways even with a fraction of the radiation of a usual CT, since the only thing that needs to be imaged in that setting is the air--bronchial wall interface, and that task may be accomplished with very low ionizing radiation dosage. Thus, such imaging methods could theoretically have potential as a noninvasive research tool to augment pulmonary function tests or quantitative video bronchoscopy[@b1-jaa-5-061] in the future evaluation of bronchial dynamics and physiological responses to therapies.
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![Acute bronchospasm on a computed tomography scan. (**A**--**C**) Baseline computed tomography images of the trachea, carina, and main bronchi. (**D**--**F**) Computed tomography images during acute bronchospasm at the trachea (arrow up), carina (arrow sideways), and main bronchi (right bronchus: arrow down). (**G**--**I**) Computed tomography images of the trachea, carina, and main bronchi 10 minutes after the administration of albuterol, which show resolution back to baseline.](jaa-5-061f1){#f1-jaa-5-061}

###### 

Quantitative assessment of patient airways

                 Baseline radius (cm)   Radius during spasm (cm)   Baseline area (cm^2^)   Area during spasm (cm^2^)   Percent change in area
  -------------- ---------------------- -------------------------- ----------------------- --------------------------- ------------------------
  Trachea                                                          16 × 20                 9.1 × 17.1                  −51.37%
  Carina                                                                                                               
   Left          4.0                    3.25                       50.27                   33.18                       −34.0%
   Right         5.1                    4.10                       81.71                   52.81                       −35.37%
  Main bronchi                                                                                                         
   Left          4.3                    2.45                       58.09                   18.86                       −67.53%
   Right         4.0                    2.10                       50.27                   13.85                       −72.45%
